Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in all living cells and has been the subject of substantial published research across metabolic biology, aging biology, and cellular energy metabolism. NAD IV research — alongside subcutaneous, nasal, and oral precursor delivery models — has demonstrated that delivery route produces meaningfully different pharmacokinetic profiles, tissue distribution patterns, and experimental outcomes in published research models. This overview summarizes what the published research literature documents about each delivery route, to assist researchers in evaluating which models are relevant to their experimental questions.

Why Delivery Route Matters for NAD+ Research Design

NAD+ is a large, charged molecule (molecular weight 663.4 Da) that does not readily cross cell membranes or the intestinal epithelial barrier in its intact form. This physicochemical reality has significant implications for experimental research design: the bioavailability and tissue distribution of exogenously administered NAD+ vary substantially depending on the administration route, and these differences can produce meaningfully different experimental outcomes across research models.

Published pharmacokinetic research has characterized the behavior of NAD+ and its precursors under different delivery conditions, providing a foundation for experimental design decisions. Researchers working in NAD+ biology need to understand these pharmacokinetic differences to select models that are appropriate to their research questions — whether that question relates to rapid systemic exposure, sustained tissue-level changes, CNS compartment access, or long-term metabolic flux.

Intravenous Administration in Clinical Research Models

Intravenous (IV) administration of NAD+ has been the delivery route used in published clinical research models where rapid systemic availability and high peak plasma concentrations are experimental objectives. IV administration bypasses the bioavailability constraints of enteral routes, delivering intact NAD+ directly to the systemic circulation.

Published clinical research, including studies in Nature Communications and Cell Metabolism, has characterized the pharmacokinetics of IV NAD+ in human subjects in research settings. These studies document rapid increases in whole-blood NAD+ concentrations following IV administration, with a distribution phase followed by metabolic conversion to downstream metabolites including NAM (nicotinamide), NMN, and ADPR. The plasma half-life of intact NAD+ following IV administration is relatively short due to rapid enzymatic processing by ectonucleotidases and other extracellular enzymes.

Published clinical research on IV NAD+ has been conducted primarily in academic medical and research settings, under institutional review and appropriate clinical research oversight. IV NAD+ is not an approved therapeutic and is investigated as a research methodology tool in clinical research models. Published studies using this route include investigations of NAD+ metabolism in aging biology research, published in journals including Cell Reports and Journal of Clinical Investigation.

Subcutaneous Administration in Animal Studies

Subcutaneous (SC) administration has been extensively used in preclinical NAD+ research in animal models, particularly rodent studies. SC administration provides a more gradual absorption profile than IV, with lower peak plasma concentrations but a longer absorption phase, which may be advantageous for experimental paradigms examining sustained systemic exposure.

Published rodent research has employed SC NAD+ administration in studies of metabolic biology, mitochondrial function, and aging-related biological parameters in mice. Studies published in Cell Metabolism, Science, and affiliated journals have used SC NAD+ or NMN administration in rodent models to investigate systemic and tissue-level NAD+ content changes. The SC route is practical for repeated dosing paradigms in rodent studies and is well-characterized in terms of tissue distribution in the preclinical literature.

Published SC administration research has documented variable tissue penetration across different organ compartments, with liver and muscle tissue showing greater NAD+ content changes in some published rodent studies compared to brain tissue — a finding with implications for research designs where CNS compartment access is a variable of interest.

Nasal Delivery: Emerging Research

Nasal delivery of NAD+ has emerged as a research-investigated route of interest due to the potential for direct transport along olfactory and trigeminal pathways, which may offer a route to CNS compartment exposure that bypasses the blood-brain barrier constraints that limit systemic delivery to the brain.

Published research on intranasal NAD+ delivery has examined this route as a potential method for increasing CNS NAD+ content in research models. Studies in animal models have investigated intranasal NMN and NAD+ delivery in the context of neurobiological research, with publications examining brain tissue NAD+ content following intranasal administration compared to systemic routes. This is an emerging area of the published research literature; the body of evidence is smaller and less mature than for IV or SC routes, and methodological standardization across research groups is ongoing.

The intranasal route raises distinct formulation considerations compared to parenteral routes: pH, osmolality, mucosal tolerability, and nasal mucociliary clearance all affect delivery efficiency. Published formulation research for intranasal NAD+ has investigated these parameters in preclinical models, and the published findings inform ongoing research design decisions in this area.

Oral Precursor Studies: NMN and NR

Because intact NAD+ has poor oral bioavailability — attributed to limited intestinal uptake of the intact molecule and first-pass degradation — published research has extensively investigated orally administered precursors, particularly nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), as strategies for raising tissue NAD+ content in research models.

NMN and NR are biosynthetic precursors to NAD+ via the salvage pathway and the Preiss-Handler pathway, respectively. Published pharmacokinetic research on oral NMN, including studies published in Cell Metabolism (Yoshino et al., 2021), has characterized the absorption, distribution, and metabolic conversion of orally administered NMN in human subjects in clinical research settings. Similarly, published NR pharmacokinetic research, including work by Trammell et al. published in Nature Communications (2016), has characterized the metabolic fate of orally administered NR and its conversion to NAD+ and downstream metabolites in blood and tissue compartments in human clinical research subjects.

These published studies document that oral NMN and NR administration raises circulating NAD+ metabolite levels in human research subjects, though the magnitude and tissue-specificity of these effects vary across published studies, and the relationship between circulating metabolite changes and intracellular NAD+ in target tissues remains an active area of investigation.

Supply Format for Research

Struck Bio Labs supplies NAD+ in two research formats designed to support different experimental protocols:

• NAD+ 1000mg lyophilised vial — high-concentration lyophilised format for laboratory reconstitution and use in research protocols requiring parenteral or solution-phase administration models
• NAD+ Nasal Spray 4500mg — prepared nasal spray format for research protocols investigating intranasal delivery models

All products are supplied for laboratory research use only, with COA documentation confirming compound identity and purity.

Frequently Asked Questions

Why does NAD+ have poor oral bioavailability as an intact molecule?

NAD+ is a large, charged dinucleotide that faces multiple barriers to intact oral absorption: it undergoes degradation by intestinal enzymes (particularly alkaline phosphatase and CD73/ecto-5′-nucleotidase), and the intact molecule has limited permeability across the intestinal epithelial barrier. Published pharmacokinetic research has characterized these barriers and motivated the investigation of biosynthetic precursors (NMN, NR) as oral strategies for raising tissue NAD+ content in research models.

What published pharmacokinetic data exists for IV NAD+ in human research models?

Published clinical research, including studies in Nature Communications and Cell Metabolism, has characterized the pharmacokinetics of IV NAD+ in human research subjects, documenting rapid plasma distribution, short plasma half-life of the intact molecule, and conversion to downstream metabolites including ADPR, NAM, and NMN. These studies are conducted in academic research settings under institutional review and are available in the primary literature.

How do SC and IV routes differ in terms of experimental outcomes in NAD+ research?

Published rodent model research indicates that SC administration produces a slower, more gradual absorption profile with lower peak plasma concentrations compared to IV, while providing a more sustained absorption phase. The choice between routes in preclinical research design depends on whether the experimental objective requires rapid peak exposure (IV) or sustained systemic exposure (SC), and whether tissue distribution in specific compartments is a variable of interest. Researchers should consult the published literature for route-specific tissue distribution data relevant to their model.

What makes intranasal delivery scientifically interesting for NAD+ research?

The intranasal route is of research interest because the olfactory and trigeminal nerve pathways that traverse the cribriform plate may allow direct drug transport to the CNS, potentially bypassing the blood-brain barrier constraints that limit systemic NAD+ delivery to the brain. Published animal model research has investigated this hypothesis for NAD+ and NMN, though the field is still characterizing the magnitude and consistency of CNS delivery via this route.

What is the difference between NMN and NR as NAD+ precursors in published research?

NMN (nicotinamide mononucleotide) enters the NAD+ biosynthetic pathway via NMNAT enzymes, while NR (nicotinamide riboside) is first phosphorylated to NMN by NRK kinases before entering the same pathway. Published pharmacokinetic research (including Trammell et al., Nature Communications 2016, and Yoshino et al., Cell Metabolism 2021) has characterized the metabolic fate of each precursor in human research subjects. Both have been shown to raise blood NAD+ metabolite levels in published clinical research, with ongoing investigation into tissue-specific distribution differences.

Is the NAD+ nasal spray format suitable for animal model research?

The nasal spray format supplied by Struck Bio Labs is a prepared aqueous NAD+ formulation designed for research use. Researchers designing animal model intranasal delivery studies should evaluate the formulation’s compatibility with their experimental protocol, including species-appropriate delivery volume, nasal mucosal tolerability in their model, and institutional protocol requirements. All products are supplied for laboratory research use only.

Further Reading: NAD+ Research • Epithalon Longevity • How to Reconstitute • NAD+ – 1000mg • NAD+ Nasal Spray • Browse Cellular Research Peptides • Disclaimer